Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new publication in the Journal of the American Chemical Society (JACS) describing advances in building self-assembling protein cages with atomic precision.
Avimer Bio said the study addresses the challenge of creating predictable protein architectures when building blocks bend during assembly. The team developed algorithms that forecast how alpha-helical protein segments flex, enabling designers to use natural molecular flexibility. This produced cubic protein cages formed from four trimeric protein blocks, twelve subunits in total, with molecular masses above 600 kilodaltons and stability in solution.
High-resolution cryo-electron microscopy at CNIO confirmed that the physical structures matched computational models, with resolutions of 3.0 to 3.9 angstroms and backbone deviations as low as 2 angstroms. The data validated the predicted helix-bending patterns.
The designed cages can present multiple therapeutic proteins in controlled arrangements to cluster cell receptors, supporting applications in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, and in oncology where receptor grouping can stimulate immune responses against tumours.
The platform relies on minimal changes to natural protein sequences and uses a single type of protein subunit per cage, simplifying production and supporting evaluation of immune response.
Bambusa Therapeutics prices upsized initial public offering
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
SciBase technology selected as primary endpoint in NIH-led skin exposure study
argenx reports positive Phase 2 results for FB102 in coeliac disease